^
Association details:
| Biomarker: | NRAS overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition
Excerpt:
Overexpression of NRAS in BRAF V600E HT-29 CRC cells was sufficient to confer vemurafenib/cetuximab resistance...7-fold amplification of RAS was found to be associated with a detectable decrease in the inhibition of phosphorylated ERK with 1-hour vemurafenib/cetuximab treatment (Supplementary Fig. 3C). RAS overexpression led to resistance in HT-29 xenografts as well...
DOI:
10.1158/0008-5472.CAN-17-0768
